Screener
Amylyx Pharmaceuticals, Inc. AMLX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -74.7%+12.7pp | -63.3%+20.0pp | -61.6%+39.3pp | -56.5%+27.9pp | -87.4%-36.2pp | |
| Return on invested capital | -104.3%+24.8pp | -165.3%-12.0pp | -176.3%+0.1pp | -129.9%+0.5pp | -129.1%-22.4pp | |
| Liquidity | ||||||
| Current ratio | 12.1×+3.4× | 17.9×+5.8× | 14.3×+7.6× | 13.7×+9.2× | 8.7×+4.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $2.15+14.2% | $2.47+5.1% | $3.23+33.5% | $3.56+23.4% | $1.88-51.0% | |
| Valuation | ||||||
| Market capitalization | $2.7B+269% | $1.54B+390% | $1.33B+412% | $1.45B+558% | $571.39M+343% | |
| Price / book | 11.3×+6.9× | 5.6×+4.1× | 4.3×+2.8× | 4.4×+3.2× | 3.4×+2.9× |
FAQ
- What are Amylyx Pharmaceuticals, Inc.'s profit margins?
- Amylyx Pharmaceuticals, Inc. (AMLX) runs a 100.0% gross margin and a -47349.8% operating margin, with a -45096.2% net margin.
- Where do Amylyx Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Amylyx Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.